11 March 2019

GLYXAMBI® on PBS SGLT2i + DPP4i combination containing JARDIANCE® and TRAJENTA®



Clinicians have welcomed the Pharmaceutical Benefits Scheme (PBS) listing of the type 2 diabetes medicine that combines JARDIANCE® (empagliflozin) and TRAJENTA® (linagliptin) in a once-daily tablet

To read the rest of this article you need to be a Medical Republic Member and registered with AHPRA, Please login below if you have an account or sign up to join.

Join Now / Login